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Objectives: To characterize the variations of serum osteoprotegerin (OPG) and RANK ligand (RANKL) with
sexual development in adolescent girls, and to estimate their associations with bone turnover and bone mineral
density (BMD).
Design and methods:We studied 300 girls evaluated at 13 and 17 years of age. Fasting blood samples were
collected and the following substances were quantified: RANKL, OPG, C-terminal telopeptide of type I collagen
(CTX), andprocollagen type INpropeptide (PINP). BMDwasmeasured at the distal forearm. Correlation coefficients
were used to quantify associations between those variables at 13 and 17 years of age. Random-effects linearmodels
were used to quantify associations between bone parameters and sexual development (years from menarche).
Results: RANKL was positively correlated with bone resorption (CTX) in early and late adolescence (r13 = 0.15
and r17 = 0.23) and the OPG/RANKL ratio correlated inversely with CTX at 17 (r17 = −0.24). No significant
associations were found between RANKL and OPG and bone formation (PINP). In early adolescence, there was an
inverse correlation of BMDwith CTX (r13 =−0.52) but no significant correlations were found between osteoclast
regulators and BMD. We observed a linear decrease in serum RANKL with increasing sexual development
(−0.09 pmol/L per year, 95% CI:−0.10,−0.07) alongside an increase in OPG (0.02 pmol/L, 95% CI: 0.01, 0.04).
Conclusions: Serum RANKL and OPG levels varied markedly with sexual development in adolescence. These
cytokines were not predictive of bone turnover or BMD at 13, but serum RANKL bioactivity was associated with
bone resorption in late adolescence.© 2014 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.Introduction
Fracture risk combines genetic background with a complex set of
exposures that act throughout the life course, influencing the resistance
of bone to trauma [1]. Bone strength is the complex end result of size,
morphology, material properties and peak bone mass attained during
the first three decades of life [2], in addition to subsequent mineral
loss. Understanding how bone dynamics evolves early in life is a key
component of research on the etiology of adult bone fragility. Theactivator of nuclear factor kB li-
rum C-terminal telopeptide of
ergy X-ray absorptiometry.
demiology, Predictive Medicine
ameda Prof. Hernâni Monteiro,
ists. Published by Elsevier Inc. All rigpotential for prevention is particularly interesting in the female gender,
where the burden of fragility fractures is disproportionately high [3].
The final physical properties of bone tissue are dependent on its
continuous turnover [4]. In adults, the main homeostatic mechanism
driving bone dynamics at the local level is remodeling, which involves
coupling of bone formation and resorption in such a way that overall
mineral mass remains fairly constant [4]. During childhood, in addition
to remodeling, growth demands for substantial changes in bone size
and shape that are achieved throughmodeling, inwhichmatrix synthesis
and degradation take place in different locations within the bone tissue
and are thus uncoupled [5]. Since modeling is a vigorous process that
results in rapid longitudinal changes in bone structure and material,
bone is an even more dynamic organ during childhood and adolescence.
Bone status can be characterized by physical properties that reflect the
cumulative process of bone accrual up to the time of measurement, and
also by turnover parameters, which are dynamic measures of short-termhts reserved.
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tissue level is the osteoprotegerin (OPG)/receptor activator of nuclear
factor kB (RANK)/RANK-ligand (RANKL) system, which mediates the
local effects of systemic modulators, such as hormones and cytokines
[8,9]. Throughout the life course, this system is essential for bone turn-
over since the relative expression of RANKL and its decoy receptor OPG
regulates osteoclast differentiation, activation and survival [8,10]. There
is evidence that thesemediatorsmay have a particularly relevant role in
early life, as they are expressed by hypertrophic chondrocytes in epiph-
yseal plates, probably regulating linear bone growth [11]. Despite their
essential role in bone metabolism [12,13], little is known about how
circulating levels of these cytokines evolve before peak bone mass or
on whether they directly relate to bone strength and turnover markers
[14,15]. On the other hand, collagen turnover markers are indicators of
bone formation or resorption rates, although high inter- and intra-
individual variability have led to limited application in clinical practice
[16]. The International Osteoporosis Foundation and the International
Federation of Clinical Chemistry and Laboratory Medicine recently rec-
ommended the use of serum procollagen type I N propeptide (PINP)
and serumC-terminal telopeptide of type I collagen (CTX), respectively,
tomonitor treatment response in clinical trials of osteoporosis therapies
[17]. It is unclear whether this set of markers and their relative concen-
tration may also be responsive to intraindividual changes in bone
metabolism during normal growth.
During early adolescence, a stage of rapid bone accrual, sexual
maturation regulates the cessation of linear growth and the improvement
in bone mechanical resistance after peak height velocity [18]. Therefore,
changes in bone properties during adolescence should be regarded as a
function of sexual development, in addition to chronologic age. Previous
studies describing bone status and turnover parameters in adolescence
have been mostly conducted cross-sectionally in samples with wide age
ranges, impairing the detection of heterogeneity across ages or sexual
development stages [19–22]. Other studies were conducted among
children with disorders that potentially disturb normal bonemetabolism
and therefore have limited generalizability [23–25].
In the present study, our objectivewas to assess if serum levels of OPG
and RANKL predict bone turnover and forearm bone mineral density in
early and late adolescence, and to describe changes in those cytokines
in relation to chronologic age and sexual development, measured as
time from menarche.
Materials and methods
We used data from a sample of 300 adolescent girls, recruited and
followed up as part of the EPITeen prospective investigation, comprising
a cohort of adolescents born in 1990 and attending public and private
schools in Porto, Portugal.
EPITeen cohort assembly and follow-up
Recruitment of the cohort took place during the 2003/2004 school
year. All 51 schools in the city attended by children born in 1990 were
contacted and 46 agreed to provide contact details for students and
their families. Study objectives and procedures were explained in detail
in meetings with teachers and parents, as well as through written
materials. Students and their legal guardians were contacted and asked
to participate. Among the 2787 eligible adolescents identified, 78%
(2160 girls and boys) agreed to participate by providing information for
at least part of the planned protocol, which included questionnaires,
physical examination, and blood sample collection. After this early
adolescence evaluation, participants were contacted again during the
2007/2008 school year for a reevaluation using the same protocol. Of
the initial cohort, 80% completed the late adolescence assessment. In
both evaluations, written informed consent was obtained from
adolescents and legal guardians. The study protocol complied with the
Declaration of Helsinki and was approved by the Ethics Committee ofthe University Hospital of São João in Porto, Portugal. Methods have
been described in detail elsewhere [26].
The study of bone development using bone mineral density as the
main outcome has been a research area since the inception of the
cohort. Before cohort recruitment in 2003, still little was known about
the clinical significance of serum OPG and RANKL levels as regulators
of bone biology in human populations and thus the analytical measure-
ments presented in this paper were not part of the initial plan. More
recently the system's role became increasingly clear as did the limitations
in published populational evidence on the topic, especially in adoles-
cence. Since we had the consent of adolescents and guardians to investi-
gate bone development namely through the blood samples collected in
both evaluations, we were able to adapt of one of the branches of our
research plan to evolving knowledge on bone biology.
Study sample
The initial cohort included 1116 girls. Of those, 892 were evaluated
at 13 and 17 years of age and 726 had complete information on
bone mineral density and anthropometry in both evaluations.
Missing informationwas largely due to losses to follow-up or unavailabil-
ity of the bone densitometry equipment at the time of evaluation. Girls
that were not eligible for the present study were not significantly differ-
ent from the remaining cohort regarding baseline height (158.2 vs.
158.1 cm, p = 0.763) but were heavier than eligible participants at
13 years of age (54.5 vs. 52.3 kg, p = 0.001) and had higher forearm
BMD (0.367 vs. 0.358 g/cm2, p = 0.033).
For this study we conducted stratified sampling: from the 726 girls
with complete information, we selected a random sample of 150 within
each of two categories of body mass index (normal weight and over-
weight). This optionwas chosen to optimize statistical power throughout
thewhole spectrumof BMI.When testing overweight as amodifier of the
associations estimated we found no differences across BMI strata and we
opted to retain the actual sample size rather than presenting weighted
estimates for the different sampling fractions.
As a general strategy, we chose a sample size that would allow us to
detect even weak correlations (b0.2) with a statistical power near 0.80
(H0: rho = 0). Since several different correlation magnitudes could be
expected from the literature, no single sample size could be expected
to yield a constant statistical power. For our effective sample size of
300, we indexed the description to the value of correlation that would
provide a 0.80 statistical power, i.e. rho = 0.16 (significance set at
0.05, using the command power onecorrelation in Stata 13.0). Since the
null hypothesis in significance testing was of no association, which is a
low cutoff in terms of biological meaning, when interpreting the results
we valued correlations above 0.2. This means that our sample size
allowed an 80% power for all the correlations that we believed were
clinically relevant.
Even though our cohort included both genders we restricted this
study to girls. Because of lack of optimal privacy at the schools where
adolescentswere evaluated,wewere not able to assess pubertal develop-
ment through Tanner staging.Whereas in girlswewere able to overcome
this limitation through the use of menarche age, we did not have a surro-
gate for sexual development in boys of this cohort, which limited our
ability to answer the present objectives in males.
Physical examination
In both evaluations, bone mass was estimated through areal bone
mineral density (BMD), measured in g/cm2 at the distal radius of the
non-dominant forearm by dual-energy X-ray absorptiometry (DXA)
using a Lunar® Peripheral Instantaneous X-ray Imager (PIXI) device.
In the case of reported previous fracture of the non-dominant arm, the
dominant arm was the one assessed. Anthropometry was obtained
while the student stood barefoot in light indoor clothing. Weight was
measured to the nearest tenth of kilogram (Tanita® scales), and height
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stadiometer (Seca®).
Clinical and behavioral information
Clinical and behavioral characteristics were collected in both
evaluations using self-administered questionnaires. One of the question-
naires was completed at home with parental assistance and included
clinical history (chronic diseases and medication use in the previous
month) and use of vitamin or mineral supplements, including calcium
and vitamin D preparations, and a food frequency questionnaire, from
which average daily nutrient intake was converted with the software
Food Processor. Oral contraceptive use at the time of inquirywas collected
through a questionnaire filled in at school. Menarche age was also
inquired at school and time relative to menarche age in each evaluation
was estimated, as the absolute difference in years between menarche
age reported in late adolescence and the age at each assessment (e.g.
for a girl whose menarche age was 12 years and was evaluated at 13
and 17 years of age, time relative to menarche would be−1 in the first
and 5 in the second assessment).
Serum determinations
For each girl, two 12-hour overnight fasting blood samples were
collected, at 13 and 17 years of age (2003/2004 and 2007/2008, respec-
tively). Samples were drawn from an antecubital vein between 8:00
and 10:00 am, centrifuged for 15min at 1500 ×g and aliquoted. Immedi-
ately after sampleswere stored frozen at−80 ºC in the population-based
biobank at theUniversity of PortoMedical School until the day of analysis.
All analytical measurements presented in this paper were conducted in
2011–2012. In order to reduce extraneous variability, samples were
paired so that both sera of each participant were examined in the same
plate. We quantified the soluble form of receptor activator of nuclear
factor kB ligand (RANKL) with a highly sensitive assay (PromoKine,
PromoCell GmbH, Germany). This kit included an additional enhance-
ment system for the amplification of the detection signal, lowering the
detection limit to 0.02 pmol/L. RANKL levels below the limit of detection
were found in four samples at 13 and in 73 samples at 17 years of age. In
order to avoid left-censoring of the distribution due to exclusion of these
observations, we used as imputation value for these individuals a concen-
tration equal to the detection level divided by the square-root of two
(0.01 pmol/L). For quantifying osteoprotegerin (OPG) we used a kit that
quantified serum concentration of all forms of this cytokine: monomer,
dimer and bound to RANKL (RayBiotech, Inc., USA), with a detection
limit of 1 pg/mL (0.014 pmol/L). As a measure of RANKL bioactivity,
serum OPG/RANKL molar ratio was calculated after converting the
serum OPG metric concentrations (molecular weight 71 kDa) to pmol/L.
C-terminal telopeptide of type I collagen (CTX), an eight-amino acid
fragment from the C-terminal telopeptide region of the α1 chain of
type I collagenwas determinedusing a SerumCross Laps assay (Immuno-
diagnostic Systems Ltd.). The detection limit was less than 0.020 ng/mL.
Procollagen type I N propeptide (PINP) is the N-terminal extension
removed from procollagen during collagen type I synthesis. This marker
of bone formation was quantified using a Cusabio Biotech Co. kit with a
detection limit under 4.7 pg/mL. As a relative measure of resorption to
formation, we calculated the ratio between CTX and PINP concentrations
expressed as percentage.
Data analysis
Height, weight, forearm BMD and serum levels of bone parameters
were described as means and 95% confidence intervals (95% CI) at 13
and 17 years of age and as average variation per follow-up year. To assess
whether the ranks of individuals in the distributions of bone parameters
weremaintained during follow-up, we calculated Spearman's correlation
coefficients between these variables at 13 and 17. These coefficientswerealso used to quantify the crude associations between height, weight, and
BMD and all of the serum parameters at each age, as well as between
variations in these parameters from 13 to 17 years of age. Individual
trajectories of each bone parameter were graphically represented
according to time from menarche in years, and overall trajectories
were depicted using lowess regressions. In order to account for intra-
individual dependency, we quantified the associations between bone
parameters and time relative tomenarche using a random-effects linear
regression model with random intercepts fitted via maximum restricted
likelihood, using the xtmixed command in Stata 12.0.
Results
Sample characteristics
In this sample of 300 girls, 13.8% were premenarcheal at 13 years of
age and all were postmenarcheal by 17. The presence of conditions
associated with altered bonemetabolismwas reported by three adoles-
cents (1% of the sample) and included hyperthyroidism, anorexia
nervosa, and renal disease. The use of medication with a potential
deleterious effect on bone mass (inhaled corticosteroids, anticonvul-
sants, and thyroid hormone replacement therapy were reported) was
also infrequent: 2.7% of girls at 13 and 3.3% at 17 years of age. Median
(25th–75th percentiles) calcium intake was 1103 (791–1409) mg/day
and median vitamin D intake was 4.0 (2.9–5.6) μg/day. Calcium or
vitamin D supplement use was uncommon in both evaluations (1% at
13 and 0.7% at 17 years of age). At 17 years of age, 76 (25.4%) girls
reported using oral contraceptives.
Changes in bone parameters during adolescence
Between 13 and 17 years of age, forearm bone mineral density
increased on average 0.023 g/cm2 ∗ year (95% CI: 0.022, 0.025), height
0.92 cm/year (95% CI: 0.83, 1.01) and weight 1.40 kg/year (95% CI: 1.21,
1.59). RANKL changed −0.12 (95% CI: −0.13, −0.10) pmol/L ∗ year
while OPG varied on average 0.03 pmol/mL ∗ year (95% CI: 0.01, 0.04).
Mean variation in serum CTX was −0.10 (95% CI: −0.12, −0.08)
ng/mL ∗ year and PINP changed −0.34 ng/mL ∗ year (95% CI: −
0.38,−0.30) between 13 and 17 years of age (Table 1).
Correlations between osteoclast regulators, markers of turnover and bone
mineral density
Pairwise correlation coefficients between variables presented in
Table 2 were calculated cross-sectionally, at each age (r13 and r17) and
also regarding the change observed between evaluations (rchange).
Regarding associations between markers of bone turnover, at 13 years
of age, the correlation between serum RANKL and CTX was positive and
significant and it increased by 17 years of age (r13 = 0.15 and r17 =
0.23). OPG was only weakly correlated with PINP in late adolescence
(r17 = −0.13). The OPG/RANKL ratio was inversely correlated with
serum CTX at 17 years of age (r17 =−0.24) (Table 2).
Analyzing the association between those parameters and BMD, at
13 years of age we observed an inverse and significant correlation of
CTX with BMD (r13 = −0.52), which was vastly attenuated by
17 years of age (r17 =−0.12). No significant correlations were found
between osteoclast regulators (RANKL, OPG or the OPG/RANKL ratio)
and BMD at 13 or 17 years of age (Table 2). There were no significant
longitudinal associations between osteoclast regulators or markers of
bone turnover measured at 13 and BMD at 17 years of age.
Time relative to menarche and changes in bone parameters
With the objective of exploring the possible effect of sexual develop-
ment, in addition to chronologic age, on serum levels of osteoclast regula-
tors and turnover markers, Fig. 1 presents adolescents' individual and
Table 1
Mean (95% confidence interval) values of bonemineral density, anthropometric variables, osteoclast regulators and turnovermarkers at 13 and17 years old and annual rate of change, and
correlations between values in early and late adolescence.
13 years old 17 years old Annual variation Spearman's correlation (13 v. 17)
Forearm bone mineral density (g/cm2) 0.366 0.441 0.023 0.67
(0.359, 0.372) (0.435, 0.446) (0.022, 0.025) (p b 0.001)
Height (cm) 158.5 161.4 0.92 0.91
(157.8, 159.2) (160.8, 162.1) (0.83, 1.01) (p b 0.001)
Weight (kg) 54.9 59.4 1.40 0.82
(53.7, 56.2) (58.2, 60.6) (1.21, 1.59) (p b 0.001)
RANKL (pmol/L) 0.58 0.20 −0.12 0.54
(0.52, 0.63) (0.17, 0.24) (−0.13,−0.10) (p b 0.001)
OPG (pmol/L) 0.56 0.65 0.03 0.41
(0.49, 0.63) (0.59, 0.70) (0.01, 0.04) (p b 0.001)
OPG/RANKL 3.58 26.5 7.30 0.47
(1.77, 5.40) (18.48, 34.49) (4.61, 10.00) (p b 0.001)
CTX (ng/mL) 1.48 1.15 −0.10 0.48
(1.41, 1.55) (1.09, 1.20) (−0.12,−0.08) (p b 0.001)
PINP (ng/mL) 69.2 68.1 −0.34 0.30
(68.0, 69.3) (68.0, 68.2) (−0.38,−0.30) (p b 0.001)
CTX/PINP (%) 2.1 1.7 −0.14 0.49
(2.0, 2.2) (1.6, 1.8) (−0.17,−0.11) (p b 0.001)
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17 years of age, according to time relative tomenarche (i.e. the difference
between the age at each evaluation and menarche age).
Table 3 provides the corresponding linear regression coefficients for
the effects of time relative tomenarche, taking into account the random
effect of the individual. Bone mineral density, height and weight
increased more steeply up to the time of menarche but the rates
decreased thereafter, as seen by the significant quadratic term for time
relative to menarche, which shows that menarche timing added
important information on the rate of change in addition to chronologic
age. Consistently, serum CTX and the CTX/PINP ratio decreased at a
higher rate in earlier stages of gynecologic development and at a
lower rate in post-menarcheal years. In contrast, serum RANKL, OPG
and PINP changed at an approximately constant rate throughout time
relative to menarche (i.e. menarche timing did not add relevant
information on the rate of change, in addition to the average trajectoryTable 2
Spearman's rank correlation coefficients for the associations between height, bone density and s
(rchange).
Height (cm) Weight (kg) BMD (g/cm2) RANKL (pmol/L
Height (cm) 1 r13 = 0.45c r13 = 0.18b r13 = 0.01
r17 = 0.38c r17 = −0.06 r17 = 0.09
rchange = 0.40c rchange = 0.44c rchange = −0.01
Weight (kg) 1 r13 = 0.56c r13 = −0.14a
r17 = 0.35c r17 = −0.07
rchange = 0.44c rchange = −0.08
BMD (g/cm2) 1 r13 = −0.03
r17 = −0.09
rchange = −0.01
RANKL (pmol/L) 1
OPG (pmol/L)
OPG/RANKL
CTX (ng/mL)
PINP (ng/mL)
a p b 0.05.
b p b 0.01.
c p b 0.001.predicted by chronologic age): we observed a linear decrease in serum
RANKL with increasing time relative to menarche (−0.09 pmol/L
per year, 95% CI: −0.10, −0.07) that remained significant after log-
transformation, while OPG increased linearly in this period (0.02 pmol/L
per year, 95% CI: 0.01, 0.04) and PINP changed−0.22 ng/mL per year
(95% CI:−0.26, −0.18). RANKL bioactivity, measured as serum OPG/
RANKL, increased at a higher rate with increasing sexual development,
as seen through the lowess curve, but its variance also increased substan-
tially in that period, which impaired fitting of a quadratic model.
Log-transformed OPG/RANKL was linearly associated with time relative
to menarche (Table 3).
After taking into account menarche age, no further differences were
found between girls who reported using oral contraceptives and those
who did not. Additionally, the exclusion of the 13 girls with clinical
conditions that could affect bone metabolism had no significant impact
on the results.erum parameters at 13 (r13) and 17 (r17) years of age and between annual rates of change
) OPG (pmol/L) OPG/RANKL CTX (ng/mL) PINP (ng/mL)
r13 = −0.02 r13 = −0.04 r13 = −0.14a r13 = 0.06
r17 = 0.02 r17 = −0.11 r17 = 0.03 r17 = 0.00
rchange = −0.07 rchange = −0.18b rchange = −0.38c rchange = −0.01
r13 = −0.07 r13 = 0.06 r13 = −0.37c r13 = −0.04
r17 = 0.07 r17 = 0.09 r17 = −0.19b r17 = −0.11a
rchange = −0.07 rchange = −0.08 rchange = −0.25c rchange = −0.14a
r13 = −0.03 r13 = 0.01 r13 = −0.52c r13 = −0.01
r17 = −0.01 r17 = 0.08 r17 = −0.12a r17 = −0.02
rchange = −0.11 rchange = −0.06 rchange = −0.26c rchange = −0.07
r13 = 0.05 r13 = −0.72c r13 = 0.15a r13 = −0.03
r17 = 0.08 r17 = −0.92c r17 = 0.23c r17 = 0.05
rchange = 0.03 rchange = −0.08 rchange = 0.03 rchange = 0.03
1 r13 = 0.60c r13 = 0.05 r13 = −0.11
r17 = 0.28c r17 = −0.02 r17 = −0.13a
rchange = 0.23c rchange = 0.01 rchange = 0.01
1 r13 = −0.07 r13 = −0.08
r17 = −0.24c r17 = −0.09
rchange = −0.03 rchange = −0.11a
1 r13 = −0.05
r17 = −0.01
rchange = −0.01
1
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Fig. 1. Individual trajectories and lowess regressions of anthropometric and bone parameters throughout adolescence, according to time relative to menarche (years) at each evaluation.
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In this population-based cohort of girls, serum RANKL and OPG levels
varied markedly between early and late adolescence, independently of
menarche timing. RANKL and OPG/RANKL were not correlated with
turnover markers at 13 years of age, but became associated with bone
resorption (CTX) in late adolescence.
Despite the major role of the RANK/RANKL/OPG system in the local
regulation of bone turnover, there is a lack of prospective evidence on
how serum levels of RANKL and OPG evolve throughout the life course.
The absence of data on the relation between circulating levels of these
cytokines and bone turnover is also recognized, andmore so in females
[14]. This may partly be explained by the yet uncertain significance of
serum levels of these cytokines, mainly since they have important
roles in other physiological and pathological functions, such as lactation,
adaptive immunity, tumor proliferation, and regulation of body temper-
ature [13]. Because of their unclear specificity towards bonemetabolism,
we cannot discard the hypothesis that the levels of OPG and/or RANKL
in our study also reflected concomitant processes other than local
communication within bone tissue.
Overall, we observed a decrease in serum RANKL between early and
late adolescence, accompanied by an increase in serum OPG and a
decrease in turnover markers of bone formation (PINP) and resorption
(CTX). These changes occurred concomitantly with linear growth and
with bone mineral accrual at the forearm, and are consistent with
bone remodeling taking over, in relation to modeling, as the predomi-
nant process governing bone turnover in late adolescence [5]. Our
results also suggest increasing variance in serum OPG to RANKL ratio
with sexual development, even though the rate of change in each of
those cytokines individually remained constant throughout time.
In our study, serum RANKL decreased with increasing age, as previ-
ously described in adults [15,27,28]. This finding, along with the direct
correlation of RANKL with CTX in late adolescence, brings prospective
evidence that serum RANKL is inversely related to skeletal maturity.
Our study extends previous knowledge by showing that a substantialdecrease in this cytokine is observable between 13 and 17 years of age
in healthy girls. The rate of change in serum RANKL throughout adoles-
cence was independent of sexual development, but the variance of
RANKL bioactivity in the population, measured through the OPG/
RANKL ratio, was related to gynecologic maturity. In addition to being
a key regulator in osteoclast biology, growing evidence shows that
RANKL is a critical mediator of progesterone function in mammary
gland development in animal models [29]. Therefore, besides reflecting
increasing skeletal maturity, our observation that the rate of change in
systemic RANKL bioactivity varied throughout sexual development is
also compatible with a major role in the development of a functional
mammary gland, although finer mechanistic explanations are beyond
the scope of our present data.
We observed a slight but significant increase in serumOPG throughout
adolescence, even though previous human studies do not clearly support
this finding. One of the few studies conducted in children showed
decreasing OPG levels up to 4 years of age, but constant levels from this
age onwards up to adulthood [23]. Another cross-sectional study in
adolescents found a gradual decrease in serum OPG with age but
suggested that OPG levels in the postpubertal period were similar to
those in young adults [30]. However, cross-sectional studies are clearly
less robust for the estimation of average trajectories than our prospective
design, since they underestimate underlying longitudinal changes [31].
Our finding of a weak association between serum levels of OPG and
RANKL may be explained by a physiological dissociation between the
relative expression of these cytokines during growth, previously reported
in epiphyseal plates [11].
Most likely as a consequence of decreasing linear growth and bone
modeling rates, averageCTXandCTX/PINP levels in our sample decreased
from early to late adolescence, in the overall sample, and a plateau was
found in girls of older gynecologic age. This decreasing intensity of bone
resorption towards the end of adolescence, because of diminishing
rate or extension ofmatrix degradation, is consistentwith the attainment
of skeletal maturity, and has been previously described using cross-
sectional evidence [22,32,33]. It is also compatible with our observation
Table 3
Fixed and random effects linear regression parameters for the associations between anthropometric and bone parameters and time relative to menarche.
Fixed effects Random effects
Intercept Time (years) Squared time (years2) Individual-level standard-deviation
BMD (mg/cm2)
Model 0 402a – – 25.2
Model 1 348a 21.8a – 39.2
Model 2 343a 31.4a −1.8a 40.8
Height (cm)
Model 0 160.0a – – 5.4
Model 1 157.7a 0.86a – 5.6
Model 2 157.4a 1.62a −0.14a 5.6
Weight (kg)
Model 0 57.2a – – 9.8
Model 1 53.7a 1.35a – 9.8
Model 2 53.3a 2.44a −0.21a 9.8
RANKL (pmol/L)
Model 0 0.39a – – 0.17
Model 1 0.62a −0.09a – 0.26
OPG (pmol/L)
Model 0 0.60a – – 0.45
Model 1 0.54a 0.02a – 0.45
Log (OPG/RANKL)
Model 0 0.97a – – 0.32
Model 1 −0.25 0.48a – 1.07
CTX (ng/mL)
Model 0 1.31a – – 0.34
Model 1 1.60a −0.11a – 0.33
Model 2 1.63a −0.19a 0.01a 0.33
PINP (ng/mL)
Model 0 68.7a – – 0.40
Model 1 69.2a −0.22a – 0.59
CTX/PINP (%)
Model 0 1.91a – – 0.51
Model 1 2.31a −0.16a – 0.49
Model 2 2.35a −0.26a 0.02a 0.49
a p b 0.001.
1045R. Lucas et al. / Clinical Biochemistry 47 (2014) 1040–1046of an inverse correlation between BMD and CTX. We observed a small
decrease in average PINP levels throughout adolescence, with no relation
tomenarche timing. This is in agreement with a previous study, in which
a PINP peak in girlswas found from10 to 13 years of age (coincidingwith
peak height velocity) and then decreased at a lower rate up to early
adulthood [34].
In addition to the expected average increase in height and forearm
BMDbetween 13 and 17 years of age in thewhole sample, we observed
a lower yearly rate of change in height as well as in bone density in girls
with more advanced sexual development. Early maturing adolescents
have younger average age at peak height and bone accrual velocities
and, in the present sample, the fastest changes in bone size and miner-
alization probably occurred before 13 years of age [18,35]. Additionally,
it is well-known that linear growth peaks earlier than bone accrual
velocity [36,37], which likely explains our stronger association of
gynecologic age with BMD than with height. Overall, we observed weak
correlations between forearm BMD and serum parameters, namely
osteoclast-regulating cytokines and PINP, in early and late adolescence.
This dissociation is compatible with BMD being the result of accumulated
exposures throughout life, while serum parameters are comparatively
obtained as instantaneous measurements.
As dynamic measures, serum parameters of bone turnover may be
subject to substantial variation, independently of meaningful differences
between individuals or measurements [9]. We minimized preanalytical
variability by collecting samples between 8 and 10 am and after a
12-hour overnight fast, using the same protocol in both evaluations and
standardizing specimen collection, processing and storage. Additionally,
these sources of variability are more relevant at the individual
level, when comparisonswith reference values or prognosismonitoring
are the aim. This study aimed at describing relative changes in bone
parameters from early to late adolescence and to assess the correlations
between them rather than establishingnormative values. Sincewe haveno reason to believe that the ranks of individuals in the distributions
were differentially affected, we do not think that intra-assay variability
has substantially biased our conclusions. Another important aspect is
that we assumed that individual variations in serum parameters could
be validly described using linear trajectories. Although other trajectories
are possible, previous studies have described nearly linear age-related
decreases in bone turnover markers in the 13–17 year range [22,32,34].
Finally, due to the evaluation setting, we used peripheral dual-energy
X-ray absorptiometry to estimate bone density. The main implication is
that intraindividual differences in forearm areal BMD are partly due to
linear growth rather than to changes in intrinsic bone strength. However,
this is not a disadvantage since bone size is also an important determinant
of overall resistance to fracture [38].
Prospective cohort studies are subject to differential losses to follow-
up as supported by the comparison we present in the Materials and
methods section. Also, closed cohorts by design cannot account for under-
lying changes in the source population. Ultimately the extent to which
the cohort represents the source population throughout follow-up is
likely to decrease over time but we believe that this does not preclude
the generation of epidemiological evidence in this particular case since
our main objective was not to describe normative values, which would
require representativeness. Our goal in this study was to estimate associ-
ations betweenmarkers of bone development and average trajectories in
a community-based cohort of teenagers, thereby improving knowledge
beyond the clinical scope. We believe that this is conveyed by the gener-
ally healthy profile of the sample presented in the Results section. In this
casewehavenomaterial reason to believe that the associations estimated
may differ among girls whose information we could not collect.
A major advantage of our study with relation to previously published
research is that we used prospective data collected from girls born in the
same year, thereby avoiding several sources of confounding. Another
important strength of the study is that we were able to provide a
1046 R. Lucas et al. / Clinical Biochemistry 47 (2014) 1040–1046multidimensional description of bone dynamics throughout adolescence
by comprising parameters that represent different features of bone status
and metabolism. This is particularly interesting regarding OPG and
RANKL, since populational data were scarce.
In this cohort of healthy girls, serum RANKL and OPG levels varied
markedly with sexual development in adolescence. These cytokines
were not predictive of bone turnover or bone mineral density at
13 years of age, but serum RANKL bioactivity was associated with
bone resorption in late adolescence.
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